#1 Clinical Trials Search in Europe

Oxcarbazepine

Oxcarbazepine, a medication commonly used to treat seizures, has been the subject of several clinical trials exploring its potential in various neurological conditions. These trials aim to evaluate its effectiveness, safety, and tolerability in treating conditions such as bipolar disorder, peripheral neuropathic pain, and trigeminal neuralgia. The studies also investigate different formulations of oxcarbazepine, including extended-release versions, to improve patient outcomes and adherence to treatment.

Table of Contents

What is Oxcarbazepine?

Oxcarbazepine is a medication primarily used to treat certain types of seizures and other neurological conditions. It belongs to a class of drugs known as anticonvulsants or antiepileptics. Oxcarbazepine is also known by its brand names, including Trileptal® and Oxtellar XR®[1][2]. These different names refer to the same active ingredient but may represent different formulations or extended-release versions of the drug.

Medical Conditions Treated with Oxcarbazepine

Oxcarbazepine is used to treat various medical conditions, including:

  • Epilepsy: Specifically, it’s used for partial-onset seizures, which are seizures that start in one area of the brain[3].
  • Bipolar Disorder: It’s used as a mood stabilizer in bipolar depression[1][4].
  • Trigeminal Neuralgia: This is a condition causing severe facial pain[2].
  • Neuropathic Pain: This includes pain caused by damage to the nerves, such as in conditions like peripheral neuropathy and postherpetic neuralgia (pain that persists after a shingles outbreak)[5].

Interestingly, there has also been research into using oxcarbazepine for treating bronchial asthma, although this is not a common use and requires further study[6].

How Oxcarbazepine Works

Oxcarbazepine works by stabilizing electrical activity in the brain. It does this by blocking sodium channels, which are like tiny gates that control the flow of sodium ions in and out of nerve cells. By blocking these channels, oxcarbazepine helps to calm overactive nerve cells, reducing the likelihood of seizures and helping to stabilize mood in conditions like bipolar disorder[1][4].

In the case of neuropathic pain and trigeminal neuralgia, oxcarbazepine is thought to work by dampening the pain signals sent by damaged or irritated nerves[5][2].

Forms and Dosage

Oxcarbazepine comes in several forms:

  • Tablets (immediate-release)[7]
  • Extended-release tablets (Oxtellar XR®)[2]
  • Oral suspension (liquid form)[8]

The dosage varies depending on the condition being treated, the patient’s age, and other factors. It’s typically started at a lower dose and gradually increased as needed. For example, in one study for bipolar depression, patients started with 600mg daily, which was then increased to 900mg daily[4]. Always follow your doctor’s instructions regarding dosage.

Effectiveness of Oxcarbazepine

Research has shown oxcarbazepine to be effective in treating various conditions:

  • For partial-onset seizures in children, long-term studies have shown it to be safe and effective[3].
  • In bipolar disorder, it has shown promise as a mood stabilizer[1].
  • For trigeminal neuralgia, extended-release oxcarbazepine (Oxtellar XR®) has been studied for its potential to improve quality of life and reduce pain[2].
  • In neuropathic pain conditions, oxcarbazepine has shown potential to reduce pain intensity[5].

Potential Side Effects

Like all medications, oxcarbazepine can cause side effects. Common side effects may include:

  • Dizziness
  • Drowsiness
  • Headache
  • Nausea
  • Double vision

More serious side effects, though rare, can include allergic reactions, low sodium levels in the blood, and mood changes. It’s important to discuss any side effects with your healthcare provider[2].

Ongoing Research and Future Potential

Research on oxcarbazepine is ongoing, exploring its potential in various areas:

  • Its effect on brain-derived neurotrophic factor (BDNF) levels in bipolar disorder, which could indicate a potential neuroprotective role[4].
  • Its use in extended-release form for trigeminal neuralgia, which could improve treatment adherence and potentially reduce side effects[2].
  • Its potential in treating bronchial asthma, although this is still in early research stages[6].

These ongoing studies highlight the continued interest in understanding and expanding the potential uses of oxcarbazepine in various medical conditions.

Aspect Details
Conditions Studied Bipolar disorder, peripheral neuropathic pain, trigeminal neuralgia, partial onset seizures
Formulations Immediate-release, extended-release (Oxtellar XR)
Primary Outcomes Pain reduction, seizure frequency, treatment effectiveness, bioequivalence, BDNF levels
Safety Assessments Adverse events, laboratory tests, vital signs, ECGs, long-term tolerability
Special Populations Children with partial onset seizures
Comparison Studies Bioequivalence studies under fasting and fed conditions
Unique Aspects Investigation of neuroprotective effects, impact on quality of life

FAQ

  • What conditions are being studied in clinical trials using oxcarbazepine? Clinical trials are investigating oxcarbazepine for various conditions, including bipolar disorder, peripheral neuropathic pain, trigeminal neuralgia, and partial onset seizures in children.
  • Are there different formulations of oxcarbazepine being tested? Yes, several trials are comparing different formulations of oxcarbazepine, including immediate-release and extended-release versions, to evaluate their bioequivalence and effectiveness.
  • What are some of the primary outcomes measured in these trials? Primary outcomes often include changes in pain levels, seizure frequency, treatment effectiveness, bioequivalence measures, and changes in serum Brain-Derived Neurotrophic Factor (BDNF) levels.
  • How is the safety of oxcarbazepine being evaluated in these trials? Safety is assessed through monitoring adverse events, laboratory tests, vital signs, electrocardiograms (ECGs), and evaluating the tolerability of the medication over extended periods.
  • Are there any trials specifically focused on children? Yes, there is a long-term safety and tolerability study of oxcarbazepine as adjunctive therapy in children with inadequately controlled partial onset seizures.

Ongoing Clinical Trials on Oxcarbazepine

  • Study on the Effects of Sirolimus and Drug Combination for Children Under 4 Months with Tuberous Sclerosis Complex

    Recruiting

    2 1 1 1
    Investigated drugs:
    Austria Germany

Glossary

  • Bioequivalence: The property of two drug products having the same rate and extent of absorption, making their effect essentially the same.
  • Brain-Derived Neurotrophic Factor (BDNF): A protein that plays a role in the survival of nerve cells and is involved in the growth, maturation, and maintenance of these cells.
  • Trigeminal Neuralgia: A chronic pain condition that affects the trigeminal nerve, which carries sensation from your face to your brain, causing intense facial pain.
  • Peripheral Neuropathic Pain: Pain caused by damage or disease affecting the peripheral nervous system, which includes nerves outside the brain and spinal cord.
  • Adjunctive Therapy: Additional treatment used together with the primary treatment to increase its effectiveness.
  • Extended-Release: A formulation of a drug designed to release the active ingredient slowly over time, allowing for less frequent dosing.
  • Bipolar Disorder: A mental health condition characterized by extreme mood swings that include emotional highs (mania or hypomania) and lows (depression).
  • Partial Onset Seizures: Seizures that begin in one area of the brain and may or may not spread to other areas.

References

  1. https://clinicaltrials.gov/study/NCT03567681
  2. https://clinicaltrials.gov/study/NCT03374709
  3. https://clinicaltrials.gov/study/NCT01051193
  4. https://clinicaltrials.gov/study/NCT02456896
  5. https://clinicaltrials.gov/study/NCT01302275
  6. https://clinicaltrials.gov/study/NCT00142025
  7. https://clinicaltrials.gov/study/NCT00849797
  8. https://clinicaltrials.gov/study/NCT01702623